BACKGROUND. Current recommendations for prophylaxis of Pneumocystis carinii pneumonia (PCP) are based on data from patients who have had at least one episode of PCP (secondary prevention). We designed a study to determine the efficacy and side effects of inhaled pentamidine in the primary prevention of PCP. METHODS. Two hundred twenty-three patients sero-positive for human immunodeficiency virus (HIV) who had the acquired immunodeficiency syndrome (AIDS) but not PCP, who had advanced AIDS-related complex, or who had less than 0.2 x 10(9) CD4-positive lymphocytes per liter received either 300 mg of pentamidine isethionate or 300 mg of sodium isethionate every 28 days by inhaler. The proportion of patients surviving without PCP was analyzed with the log-rank test as a function of time spent in the trial, according to the intention to treat with either placebo or pentamidine. RESULTS. The third of five planned interim analyses showed a significant difference in the occurrence of PCP, with 8 cases in pentamidine group and 23 in the placebo group (nominal P value = 0.0021). There were no deaths within 60 days of the diagnosis of PCP and no significant differences in survival between groups. Approximately 53 inhalations were needed to prevent one episode of pneumonia. Thirty-eight of 114 patients given pentamidine (33 percent) and 7 of 109 given placebo (6 percent) had moderate-to-severe coughing during inhalations (two-tailed P less than 0.00001), which caused 4 patients given pentamidine (3.5 percent) to discontinue taking it. CONCLUSIONS. A dose of 300 mg of aerosolized pentamidine given every four weeks was well tolerated and 60 to 70 percent effective in preventing a first episode of PCP in patients with HIV infection.
Source Information
Division of Infectious Diseases, Hopital Cantonal Universitaire, Geneva, Switzerland.
This article has been cited by other articles:
Wei, C. C-Y, Gardner, S., Rachlis, A., Pack, L. L., Chan, C. K. N.
(2001). Risk Factors for Prophylaxis Failure in Patients Receiving Aerosol Pentamidine for Pneumocystis carinii Pneumonia Prophylaxis. Chest
119: 1427-1433
[Abstract][Full Text]
Ledergerber, B., Mocroft, A., Reiss, P., Furrer, H., Kirk, O., Bickel, M., Uberti-Foppa, C., Pradier, C., d'Arminio Monforte, A., Schneider, M. M.E., Lundgren, J. D.
(2001). Discontinuation of Secondary Prophylaxis against Pneumocystis carinii Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. NEJM
344: 168-174
[Abstract][Full Text]
Furrer, H., Egger, M., Opravil, M., Bernasconi, E., Hirschel, B., Battegay, M., Telenti, A., Vernazza, P. L., Rickenbach, M., Flepp, M., Malinverni, R., The Swiss HIV Cohort Study,
(1999). Discontinuation of Primary Prophylaxis against Pneumocystis carinii Pneumonia in HIV-1-Infected Adults Treated with Combination Antiretroviral Therapy. NEJM
340: 1301-1306
[Abstract][Full Text]
Fishman, J. A.
(1998). Prevention of Infection Due to Pneumocystis carinii. Antimicrob. Agents Chemother.
42: 995-1004
[Full Text]
Bozzette, S. A., Finkelstein, D. M., Spector, S. A., Frame, P., Powderly, W. G., He, W., Phillips, L., Craven, D., van der Horst, C., Feinberg, J., The NIAID AIDS Clinical Trials Group,
(1995). A Randomized Trial of Three Antipneumocystis Agents in Patients with Advanced Human Immunodeficiency Virus Infection. NEJM
332: 693-699
[Abstract][Full Text]
Hoover, D. R., Saah, A. J., Bacellar, H., Phair, J., Detels, R., Anderson, R., Kaslow, R. A., The Multicenter AIDS Cohort Study,
(1993). Clinical Manifestations of AIDS in the Era of Pneumocystis Prophylaxis. NEJM
329: 1922-1926
[Abstract][Full Text]
Girard, P.-M., Landman, R., Gaudebout, C., Olivares, R., Saimot, A. G., Jelazko, P., Gaudebout, C., Certain, A., Boue, F., Bouvet, E., Lecompte, T., Jean-Coulaud, P., The PRIO Study Group,
(1993). Dapsone-Pyrimethamine Compared with Aerosolized Pentamidine as Primary Prophylaxis against Pneumocystis carinii Pneumonia and Toxoplasmosis in HIV Infection. NEJM
328: 1514-1520
[Abstract][Full Text]
Weinberger, S. E.
(1993). Recent Advances in Pulmonary Medicine- Second of Two Parts. NEJM
328: 1462-1470
[Full Text]
Paar, D., Masur, H.
(1992). Advances in the Management of Major Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection. Journal of Pharmacy Practice
5: 131-142
(1991). PRIMARY PREVENTION OF PCP USING INHALED PENTAMIDINE. JWatch General
1991: 3-3
[Full Text]
Previous
